The individual first received their multiple myeloma (MM) diagnosis in 2019. A new case study details a rare instance of a patient who developed hyperammonemia after achieving complete remission from ...

We thank Harold Pupko for raising several relevant points concerning our article.1 Valproate-induced hyperammonemic encephalopathy is a well- described phenomenon, but its precise incidence is unknown ...

The Food and Drug Administration (FDA) has approved a new indication for Carbaglu ® (carglumic acid; Recordati Rare Diseases) for use as adjunctive therapy in the treatment of acute hyperammonemia due ...

Purpose of study– Transient hyperammonemia of the newborn can lead to an overwhelming and potentially fatal illness. The etiology of this condition is obscure although hypoxia, immature urea cycle and ...

Science Translational Medicine publishes first-in-human clinical data and supporting preclinical data for SYNB1020, Synlogic's synthetic Biotic™ medicine in development as a potential treatment for ...

(HealthDay News) – For patients with cirrhosis, hyperammonemia induced by an amino acid challenge (AAC) leads to an increase in daytime subjective sleepiness and changes in sleep patterns. Alessia ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synlogic, Inc., (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced that ...

Ocera has received Fast Track Designation and Orphan Drug Status and plans to initiate Phase 2 studies with OCR-002 in 2011. SAN DIEGO, Dec. 15, 2010 /PRNewswire/ -- Ocera Therapeutics, Inc. announced ...

According to a recent Future Market Insights analysis, the global hyperammonemia treatment market is anticipated to reach a valuation of US$ 1,318.05 Million in 2023 and US$ 2,100 Million by 2033, ...

Saleh Alqahtani and colleagues have provided a welcome reminder that hyperammonemia is a common side effect of valproate therapy.1 However, I am not convinced that hyperammonemia is a benign ...